Clik here to view.
GVK BIO签署收购 Vanta Bioscience的确定性协议
印度海德拉巴德 (美国商业资讯) — 亚洲领先的发现和研发组织GVK BIO宣布签署收购Vanta Bioscience的确定性协议，Vanta是一家总部位于印度钦奈的合同研究组织，提供临床前GLP毒理学和安全性评估全套服务。 Vanta 符合OECD GLP、ISO、USFDA GLP (21 CFR Part 58 rev....
View ArticleClik here to view.
Taiyo Pacific Partners成为Peptidream, Inc.的主要股东，所持股份超过5%
东京 –(美国商业资讯)–Taiyo Pacific Partners今天宣布，该公司已累计持有Peptidream, Inc. (4587) 5%以上的股份，成为Peptidream的第二大机构股东。Peptidream渴望成为探索和开发全新高效胜肽疗法的全球领先者，以解决患者未满足的医疗需求并改善全球患者的生活质量。Taiyo Pacific...
View ArticleClik here to view.
Study Shows Positive Clinical and Potential Economic Outcomes with V.A.C....
SAN ANTONIO Acelity is pleased to announce the publication of a peer-reviewed study that suggests V.A.C. VeraFlo™ Therapy (NPWTi-d) may be more cost effective than standard V.A.C.® Therapy (NPWT)....
View ArticleClik here to view.
Takeda Announces Abstracts for ADCETRIS® (brentuximab vedotin) in Hodgkin...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502) today announced that abstracts of interest from studies on VELCADE® (bortezomib), ADCETRIS® (brentuximab vedotin)...
View ArticleClik here to view.
Avedro Granted Korean Approval for its KXL® Cross-Linking System for Lasik Xtra®
WALTHAM, Mass. Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company announces today that it has been granted approval from the South Korean Ministry of Food and Drug...
View ArticleClik here to view.
R-Tech Ueno: Completion of a Phase I/II Clinical Study of Recombinant Human...
TOKYO R-Tech Ueno (JASDAQ:4573): This is to announce the completion of a Phase I/II clinical study of recombinant human serum albumin-containing ophthalmic solution (development code: RU-101) for...
View ArticleClik here to view.
Ascletis Gains Exclusive China Market Rights from Presidio to Clinical Stage...
HANGZHOU, China & RESEARCH TRIANGLE PARK, NC & SAN FRANCISCO Ascletis and Presidio announced today that they have entered into an exclusive licensing agreement for Presidio’s clinical stage,...
View ArticleClik here to view.
武田宣布，ADCETRIS® (brentuximab...
马萨诸塞州坎布里奇和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE:4502)今天宣布，该公司关注的VELCADE® （硼替佐米）、ADCETRIS® (brentuximab vedotin)和研究中的口服蛋白酶体抑制剂ixazomib...
View ArticleClik here to view.
Kyoto Prize, Celebrating Its 30th Year as Japan’s Highest Private Award for...
KYOTO, Japan The non-profit Inamori Foundation (President: Dr. Kazuo Inamori) presented its 30th annual Kyoto Prize, Japan’s highest private award for global achievement, during a formal ceremony...
View ArticleClik here to view.
エリテックが大腸菌由来およびエルウィニア菌由来のアスパラギナーゼにアレルギーを持つALL患者でのGRASPA®使用についての良好な初期結果をASHにて発表へ
仏リヨン （ビジネスワイヤ） — 急性白血病および医療ニーズが満たされていないその他の腫瘍適応症を対象に革新的な「腫瘍飢餓化」治療薬の開発に当たっているフランスのバイオ製薬企業エリテック（Paris:ERYP）（Euronext Paris: FR0011471135 –...
View ArticleClik here to view.
BioCision Announces Industry’s First Automated Biospecimen Thawing System
SAN RAFAEL, Calif. BioCision, LLC, a leader in advanced products to improve biospecimen and biologics handling and standardization, today announced the availability of ThawSTAR™ automated sample...
View ArticleClik here to view.
Thailand-based SCG Acquires Stake in Liechtenstein-Based Research Company...
TRIESENBERG, Liechtenstein The Siam Cement Group (SCG), headquartered in Bangkok, Thailand, one of Asia’s largest industrial conglomerates has acquired a 20 percent stake in Lysando AG, based in...
View ArticleClik here to view.
Numurkah District Health Service Improves Safety with Spok’s Clinical...
PERTH, Western Australia Spok, Inc. today announced that Numurkah District Health Service in Victoria, Australia, is using the Spok® clinical alerting solution to improve staff safety and...
View ArticleClik here to view.
Renowned Japanese Scholar Takashi Gojobori Receives Honorary Doctorate from NCKU
TAINAN, Taiwan Dr. Takashi Gojobori, a world-renowned expert on molecular evolution and comparative genomics, received an honorary doctoral degree from National Cheng Kung University (NCKU),...
View ArticleClik here to view.
Immune Checkpoint Inhibitors Market to Witness 24.1% Annualised Growth,...
LONDON Roots Analysis has announced the addition of “Immune Checkpoint Inhibitors Market, 2014-2024” report to their offering. The study offers a comprehensive view of the emerging market of CTLA-4,...
View ArticleClik here to view.
Novel Agreement Expands Access to Pfizer’s Contraceptive, Sayana® Press, for...
NEW YORK Pfizer Inc., the Bill & Melinda Gates Foundation and the Children’s Investment Fund Foundation (CIFF) today announced an agreement that will expand access to Pfizer’s injectable...
View ArticleClik here to view.
Catalent收购Micron Technologies
新泽西州萨默塞特 (美国商业资讯)–Catalent, Inc. (NYSE:CTLT)是一家面向药物、生物制剂和消费者健康产品的先进投药技术和开发解决方案的全球领先提供商，该公司今天宣布已收购颗粒尺寸工程技术的全球领先提供商Micron Technologies。 Catalent在执行其提供最佳投药技术的战略中取得的一大重要进展，就是将Micron...
View ArticleClik here to view.
Clik here to view.
全球调研发现，欧美许多人基本上不了解胰腺癌这一主要的致死性癌症
新泽西州萨米特 (美国商业资讯) –当人们听到“癌症”这个词时，首先想到乳腺癌和肺癌，这可能不足为奇，而近期一项6个国家参与的癌症知晓度调研显示，60%的受访者几乎不知道胰腺癌这一主要的癌症杀手。胰腺癌是美国排行第四的癌症相关死因，预计到2020年，将成为美国第二大癌症死因。在欧美，胰腺癌的5年总生存率不到7%；这项生存率多年来一直很低，在美国和欧洲多数国家常见癌症生存率中位列最低之一。...
View ArticleClik here to view.
BeiGene Completes 450 Million RMB (75 Million USD) Financing
BEIJING BeiGene, LTD., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the successful completion of a financing of over 450 million...
View Article